Akero Therapeutics Inc (AKRO)

$42.12 -1.55 (-3.55%)
Market Cap 3.48B
Revenue (ttm) 0.00
Net Income (ttm) -252.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.05
Volume 947,700
Avg Vol 1,376,612
Day's Range N/A - N/A
Shares Out 79.62M
Stochastic %K 1%
Beta -0.19
Analysts Strong Sell
Price Target $76.00

Latest News on AKRO

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Stockholders to Learn More About the Investigation

Mar 6, 2025, 10:00 AM EST - 2 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Investors to Inquire about Securities Investigation

Mar 4, 2025, 10:00 AM EST - 4 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Investors to Inquire about Securities Investigation

Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 28, 2025, 7:00 AM EST - 8 days ago

Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Shareholders to Inquire about Securities Investigation

Feb 14, 2025, 10:00 AM EST - 22 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect

Feb 13, 2025, 10:00 AM EST - 23 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out

Feb 12, 2025, 10:00 AM EST - 24 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Shareholders to Learn More About the Investigation

Feb 11, 2025, 10:00 AM EST - 25 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Investors to Learn More About the Investigation

Feb 10, 2025, 10:00 AM EST - 26 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Investors to Learn More About the Investigation

Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Feb 9, 2025, 10:00 AM EST - 27 days ago

Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Investors to Connect

Feb 7, 2025, 10:00 AM EST - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation

Feb 6, 2025, 10:00 AM EST - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Investors to Reach Out

Feb 4, 2025, 10:00 AM EST - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out

Feb 3, 2025, 10:00 AM EST - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Connect

Feb 2, 2025, 10:00 AM EST - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Connect

Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jan 31, 2025, 10:00 AM EST - 5 weeks ago

Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 30, 2025, 4:05 PM EST - 5 weeks ago

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

Jan 28, 2025, 9:30 PM EST - 5 weeks ago

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

Akero: Reversal Of Cirrhosis With EFX Is A 'First' In F4 MASH Patients

Jan 28, 2025, 2:38 PM EST - 5 weeks ago

Akero: Reversal Of Cirrhosis With EFX Is A 'First' In F4 MASH Patients

Akero Therapeutics Announces Proposed Public Offering of Common Stock

Jan 27, 2025, 4:01 PM EST - 5 weeks ago

Akero Therapeutics Announces Proposed Public Offering of Common Stock

Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results

Jan 27, 2025, 12:10 PM EST - 5 weeks ago

Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results

Why did Akero (AKRO) stock soar 110% on Monday?

Jan 27, 2025, 11:30 AM EST - 5 weeks ago

Why did Akero (AKRO) stock soar 110% on Monday?

Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why

Jan 27, 2025, 9:01 AM EST - 5 weeks ago

Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why

Akero shares double after preliminary results from mid-stage trial for liver disease drug

Jan 27, 2025, 6:52 AM EST - 5 weeks ago

Akero shares double after preliminary results from mid-stage trial for liver disease drug

Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

Jan 27, 2025, 6:30 AM EST - 5 weeks ago

Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

Jan 24, 2025, 4:05 PM EST - 6 weeks ago

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

Kuehn Law Encourages Investors of Akero Therapeutics, Inc. to Contact Law Firm

Jan 24, 2025, 11:01 AM EST - 6 weeks ago

Kuehn Law Encourages Investors of Akero Therapeutics, Inc. to Contact Law Firm

Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024

Nov 15, 2024, 11:00 AM EST - 4 months ago

Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024

Akero Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 13, 2024, 4:05 PM EST - 4 months ago

Akero Therapeutics to Present at the Jefferies London Healthcare Conference

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 8, 2024, 7:00 AM EST - 4 months ago

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024

Oct 21, 2024, 7:00 AM EDT - 4 months ago

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm

Sep 30, 2024, 9:37 PM EDT - 5 months ago

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference

Sep 30, 2024, 7:00 AM EDT - 5 months ago

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference

Akero Therapeutics: Good Candidate For The MASH Basket

Sep 20, 2024, 3:37 PM EDT - 6 months ago

Akero Therapeutics: Good Candidate For The MASH Basket

Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH

Sep 9, 2024, 7:00 AM EDT - 6 months ago

Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH

Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 28, 2024, 4:05 PM EDT - 6 months ago

Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 9, 2024, 7:00 AM EDT - 7 months ago

Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm

Jun 28, 2024, 10:40 AM EDT - 9 months ago

Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics

Jun 21, 2024, 10:40 AM EDT - 9 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics

AKRO ANNOUNCEMENT: If You Have Suffered Losses in Akero Therapeutics, Inc. (NASDAQ: AKRO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Jun 16, 2024, 11:18 AM EDT - 9 months ago

AKRO ANNOUNCEMENT: If You Have Suffered Losses in Akero Therapeutics, Inc. (NASDAQ: AKRO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

AKRO INVESTOR NOTICE: Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

Jun 11, 2024, 3:46 PM EDT - 9 months ago

AKRO INVESTOR NOTICE: Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

Jun 11, 2024, 7:00 AM EDT - 9 months ago

Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024

Jun 8, 2024, 8:15 AM EDT - 9 months ago

Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024

IMPORTANT JUNE DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firm

Jun 5, 2024, 12:00 PM EDT - 9 months ago

IMPORTANT JUNE DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firm

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics

Jun 5, 2024, 11:15 AM EDT - 9 months ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firm

Jun 5, 2024, 10:20 AM EDT - 9 months ago

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firm